Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 15/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123166 | 1.00 | PDE10A (1.00) | PDE10APDE3BPDE3A | |
| SCHEMBL4404999 | 1.00 | PDE10A (1.00) | PDE10APDE3BPDE3A | |
| SCHEMBL2725365 | 1.00 | PDE10A (1.00) | PDE10APDE3BPDE3A | |
| SCHEMBL2732504 | 0.95 | PDE10A (0.90) | PDE10APDE3BPDE3A | |
| SCHEMBL4546146 | 0.95 | PDE10A (0.90) | PDE10APDE3BPDE3A | |
| SCHEMBL10064028 | 0.95 | PDE10A (0.90) | PDE10APDE3BPDE3A | |
| SCHEMBL4546144 | 0.95 | PDE10A (0.90) | PDE10APDE3BPDE3A | |
| SCHEMBL4545624 | 0.93 | PDE10A (0.87) | PDE10APDE3BPDE3A | |
| SCHEMBL10063509 | 0.93 | PDE10A (0.87) | PDE10APDE3BPDE3A | |
| SCHEMBL4545622 | 0.93 | PDE10A (0.86) | PDE10APDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120041510-A | Intracellular delivery method of functionalized modified carbon nanomaterial and light synergistic enhanced exogenous biomacromolecule | 南京林业大学 | 2025-05-27 | — | — | CN | claimed |
| US-12201711-B2 | Wax dispersions having conditioning properties | BASF SE (DE) | 2025-01-21 | — | — | US | claimed |
| EP-3801448-B1 | WAX DISPERSIONS WITH CONDITIONING PROPERTIES | BASF SE (DE) | 2024-07-10 | — | — | EP | claimed |
| CN-117777976-A | Composition, blocking removal system and blocking removal method | 中国石油化工股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | claimed |
| US-20230240956-A1 | WAX DISPERSIONS HAVING CONDITIONING PROPERTIES | BASF SE (DE) | 2023-08-03 | — | — | US | claimed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | claimed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | claimed |
| CN-115484938-A | Composition and use thereof | 博善人工智能剑桥有限公司 | 2022-12-16 | — | — | CN | claimed |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | UNIVERSITY OF SOUTH ALABAMA (US) | 2016-05-26 | — | — | US | claimed |
| EP-4312960-B1 | HAIR CONDITIONER | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122040878-A | Sealing ring for fluorine silica gel and PTFE/carbon fiber combined shaft and preparation method thereof | 宁波市迪恩光伏科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122037795-A | Polishing composition and polishing method | 东莞领航电子新材料有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130838-A1 | HAIR CARE FORMULATION | DOW SILICONES CORP (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622862-B2 | Hair conditioner formulation | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2012052556-A1 | NOVEL HALOALKOXYQUINAZOLINES, AND PREPARATION AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PFIZER INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PFIZER INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2005120514-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230240956-A1 | WAX DISPERSIONS HAVING CONDITIONING PROPERTIES | ELOVL1, ELOVL5, CUTA | PDE10A 381/4885PDE3B 1040/4885PDE3A 1065/4885 |
| US-12622862-B2 | Hair conditioner formulation | DEGS1, DSG1, SDC1 | PDE10A 4702/4885PDE3B 4687/4885PDE3A 4629/4885 |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | PDE10A 5/4885PDE3B 3/4885PDE3A 2/4885 |
| US-12201711-B2 | Wax dispersions having conditioning properties | ELOVL1, ELOVL5, CUTA | PDE10A 381/4885PDE3B 1040/4885PDE3A 1065/4885 |
| US-20260130838-A1 | HAIR CARE FORMULATION | MALT1, IRS1, SHC1 | PDE10A 1966/4885PDE3B 4396/4885PDE3A 3305/4885 |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PDE5A, PDE12, PDE2A | PDE10A 7/4885PDE3B 6/4885PDE3A 4/4885 |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | PDE4A, PDE7B, PDE2A | PDE10A 12/4885PDE3B 8/4885PDE3A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.